Article: Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

File Download

content.pdf

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1186/1471-2407-12-357
Scopus: eid_2-s2.0-84864942652
PMID: 22897928

Supplementary

Bookmarks:
- CiteULike:
  1
Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Obstetrics & Gynaecology: Journal/Magazine Articles

Title	Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
Authors	Li, C1 Liu, VWS1 2 Chiu, PM1 Chan, DW1 Ngan, HYS1 2
Issue Date	2012
Publisher	BioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/
Citation	BMC Cancer, 2012, v. 12, article no. 357 [How to Cite?] DOI: http://dx.doi.org/10.1186/1471-2407-12-357
Abstract	ABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.
Description	Provisional PDF
ISSN	1471-2407 2011 Impact Factor: 3.011 2011 SCImago Journal Rankings: 0.342
DOI	http://dx.doi.org/10.1186/1471-2407-12-357

DC Field	Value
dc.contributor.author	Li, C
dc.contributor.author	Liu, VWS
dc.contributor.author	Chiu, PM
dc.contributor.author	Chan, DW
dc.contributor.author	Ngan, HYS
dc.date.accessioned	2012-09-20T08:10:05Z
dc.date.available	2012-09-20T08:10:05Z
dc.date.issued	2012
dc.description.abstract	ABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.
dc.description.nature	published_or_final_version
dc.description	Provisional PDF
dc.identifier.citation	BMC Cancer, 2012, v. 12, article no. 357 [How to Cite?] DOI: http://dx.doi.org/10.1186/1471-2407-12-357
dc.identifier.citeulike	11104964
dc.identifier.doi	http://dx.doi.org/10.1186/1471-2407-12-357
dc.identifier.hkuros	207469
dc.identifier.issn	1471-2407 2011 Impact Factor: 3.011 2011 SCImago Journal Rankings: 0.342
dc.identifier.pmid	22897928
dc.identifier.scopus	eid_2-s2.0-84864942652
dc.identifier.uri	http://hdl.handle.net/10722/164814
dc.identifier.volume	12, article no. 357
dc.language	eng
dc.publisher	BioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/
dc.publisher.place	United Kingdom
dc.relation.ispartof	BMC Cancer
dc.rights	Creative Commons: Attribution 3.0 Hong Kong License
dc.title	Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
dc.type	Article

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Li, C</contributor.author><contributor.author>Liu, VWS</contributor.author><contributor.author>Chiu, PM</contributor.author><contributor.author>Chan, DW</contributor.author><contributor.author>Ngan, HYS</contributor.author><date.accessioned>2012-09-20T08:10:05Z</date.accessioned><date.available>2012-09-20T08:10:05Z</date.available><date.issued>2012</date.issued><identifier.citation>BMC Cancer, 2012, v. 12, article no. 357</identifier.citation><identifier.issn>1471-2407</identifier.issn><identifier.uri>http://hdl.handle.net/10722/164814</identifier.uri><description>Provisional PDF</description><description.abstract>ABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.</description.abstract><language>eng</language><publisher>BioMed Central Ltd. The Journal&apos;s web site is located at http://www.biomedcentral.com/bmccancer/</publisher><relation.ispartof>BMC Cancer</relation.ispartof><rights>Creative Commons: Attribution 3.0 Hong Kong License</rights><title>Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications</title><type>Article</type><description.nature>published_or_final_version</description.nature><identifier.doi>10.1186/1471-2407-12-357</identifier.doi><identifier.pmid>22897928</identifier.pmid><identifier.scopus>eid_2-s2.0-84864942652</identifier.scopus><identifier.hkuros>207469</identifier.hkuros><identifier.volume>12, article no. 357</identifier.volume><publisher.place>United Kingdom</publisher.place><identifier.citeulike>11104964</identifier.citeulike><bitstream.url>http://hub.hku.hk/bitstream/10722/164814/1/content.pdf</bitstream.url></item>

Author Affiliations

The University of Hong Kong Li Ka Shing Faculty of Medicine
Queen Mary Hospital Hong Kong